-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Reata Pharmaceuticals (NASDAQ:RETA) Trading Up 4.6%
Reata Pharmaceuticals (NASDAQ:RETA) Trading Up 4.6%
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) was up 4.6% during mid-day trading on Monday . The stock traded as high as $23.59 and last traded at $23.14. Approximately 14,495 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 674,305 shares. The stock had previously closed at $22.12.
Wall Street Analysts Forecast Growth
Separately, Robert W. Baird lowered their price objective on shares of Reata Pharmaceuticals from $37.00 to $27.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Reata Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $57.57.
Get Reata Pharmaceuticals alerts:Reata Pharmaceuticals Price Performance
The stock's 50-day simple moving average is $26.54 and its two-hundred day simple moving average is $29.67. The firm has a market capitalization of $843.45 million, a P/E ratio of -2.72 and a beta of 1.16.
Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) last released its quarterly earnings data on Monday, August 8th. The company reported ($2.02) EPS for the quarter, missing the consensus estimate of ($1.90) by ($0.12). Reata Pharmaceuticals had a negative net margin of 3,045.98% and a negative return on equity of 190.87%. The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $1.46 million. During the same quarter last year, the business earned ($2.00) EPS. Reata Pharmaceuticals's revenue for the quarter was down 65.7% compared to the same quarter last year. On average, analysts forecast that Reata Pharmaceuticals, Inc. will post -8.37 earnings per share for the current fiscal year.Institutional Trading of Reata Pharmaceuticals
A number of institutional investors have recently modified their holdings of RETA. US Bancorp DE boosted its position in shares of Reata Pharmaceuticals by 930.5% during the 1st quarter. US Bancorp DE now owns 1,824 shares of the company's stock valued at $60,000 after acquiring an additional 1,647 shares during the last quarter. UBS Group AG boosted its holdings in Reata Pharmaceuticals by 42.2% in the second quarter. UBS Group AG now owns 2,558 shares of the company's stock valued at $78,000 after purchasing an additional 759 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in Reata Pharmaceuticals by 51.1% in the second quarter. Macquarie Group Ltd. now owns 2,768 shares of the company's stock valued at $84,000 after purchasing an additional 936 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Reata Pharmaceuticals in the first quarter valued at approximately $141,000. Finally, Virtus ETF Advisers LLC boosted its holdings in shares of Reata Pharmaceuticals by 282.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,684 shares of the company's stock valued at $150,000 after acquiring an additional 4,198 shares during the period. 76.00% of the stock is currently owned by institutional investors.
About Reata Pharmaceuticals
(Get Rating)
Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.
See Also
- Get a free copy of the StockNews.com research report on Reata Pharmaceuticals (RETA)
- Three Consumer Stocks That Could Outperform In Q4
- Comcast is an Asset Bonanza Priced Cheap
- Will Synthetic Biology Firm Amyris Post Net Income In 2024?
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) was up 4.6% during mid-day trading on Monday . The stock traded as high as $23.59 and last traded at $23.14. Approximately 14,495 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 674,305 shares. The stock had previously closed at $22.12.
瑞塔制药股份有限公司(纳斯达克代码:Reta-Get Rating)周一午盘上涨4.6%。该股最高交易价格为23.59美元,最后报23.14美元。午盘交易中,约有14,495股易手,较674,305股的日均成交量下降了98%。该股此前收盘价为22.12美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Separately, Robert W. Baird lowered their price objective on shares of Reata Pharmaceuticals from $37.00 to $27.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Reata Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $57.57.
另外,罗伯特·W·贝尔德在8月9日星期二的一份研究报告中将Reata PharmPharmticals的股票目标价从37.00美元下调至27.00美元,并将该股的评级定为“中性”。一位股票研究分析师将该股的评级定为卖出,两位分析师给出了持有评级,四位分析师给出了买入评级。根据MarketBeat的数据,Reata PharmPharmticals目前的共识评级为持有,平均目标价为57.57美元。
Reata Pharmaceuticals Price Performance
瑞塔医药价格表现
The stock's 50-day simple moving average is $26.54 and its two-hundred day simple moving average is $29.67. The firm has a market capitalization of $843.45 million, a P/E ratio of -2.72 and a beta of 1.16.
该股的50日简单移动均线切入位为26.54美元,200日简单移动均线切入位为29.67美元。该公司的市值为8.4345亿美元,市盈率为-2.72,贝塔系数为1.16。
Institutional Trading of Reata Pharmaceuticals
瑞塔制药的机构交易
A number of institutional investors have recently modified their holdings of RETA. US Bancorp DE boosted its position in shares of Reata Pharmaceuticals by 930.5% during the 1st quarter. US Bancorp DE now owns 1,824 shares of the company's stock valued at $60,000 after acquiring an additional 1,647 shares during the last quarter. UBS Group AG boosted its holdings in Reata Pharmaceuticals by 42.2% in the second quarter. UBS Group AG now owns 2,558 shares of the company's stock valued at $78,000 after purchasing an additional 759 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in Reata Pharmaceuticals by 51.1% in the second quarter. Macquarie Group Ltd. now owns 2,768 shares of the company's stock valued at $84,000 after purchasing an additional 936 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Reata Pharmaceuticals in the first quarter valued at approximately $141,000. Finally, Virtus ETF Advisers LLC boosted its holdings in shares of Reata Pharmaceuticals by 282.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,684 shares of the company's stock valued at $150,000 after acquiring an additional 4,198 shares during the period. 76.00% of the stock is currently owned by institutional investors.
一些机构投资者最近修改了对Reta的持股。US Bancorp DE在第一季度将其在Reata PharmPharmticals的股票头寸增加了930.5%。US Bancorp DE现在拥有1,824股该公司股票,价值6万美元,此前在上个季度又购买了1,647股。瑞银集团在第二季度增持了Reata PharmPharmticals 42.2%的股份。瑞银集团目前持有该公司2,558股股票,价值7.8万美元,上一季度又购买了759股。麦格理集团有限公司在第二季度增持了51.1%的Reata PharmPharmticals股份。麦格理集团(Macquarie Group Ltd.)目前持有2,768股该公司股票,价值84,000美元,该公司在上个季度又购买了936股。合并银行在第一季度收购了Reata制药公司的新股份,价值约为141,000美元。最后,Virtus ETF Advisers LLC在第四季度增持了282.5%的Reata PharmPharmticals股票。Virtus ETF Advisers LLC现在拥有5684股该公司的股票,价值15万美元,在此期间又购买了4198股。76.00%的股票目前由机构投资者持有。
About Reata Pharmaceuticals
关于瑞塔制药公司
(Get Rating)
(获取评级)
Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.
瑞塔制药公司是一家临床阶段的生物制药公司,为患有严重或危及生命的疾病的患者识别、开发和商业化新的疗法。该公司正在开发第三阶段临床试验计划,包括用于治疗由Alport综合征引起的慢性肾脏疾病(CKD)以及与结缔组织疾病相关的一种形式的肺动脉高压的患者的甲基巴度索龙(Bardoxolone);治疗Friedreich‘s共济失调的第二阶段临床试验奥马维酮;以及针对各种形式的CKD进行第二阶段研究,如IgA肾病、1型和2型糖尿病CKD、高血压CKD、局灶性节段性肾小球硬化等。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Reata Pharmaceuticals (RETA)
- Three Consumer Stocks That Could Outperform In Q4
- Comcast is an Asset Bonanza Priced Cheap
- Will Synthetic Biology Firm Amyris Post Net Income In 2024?
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- 免费获取StockNews.com关于Reata制药的研究报告(RETA)
- 三只可能在第四季度表现优异的消费类股
- 康卡斯特是廉价的资产财源
- 合成生物学公司Amyris将在2024年实现净收益吗?
- 卡特彼勒能否在下跌的市场中走得更高?
- Dave&Buster‘s能免受高通胀和低支出的影响吗?
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《瑞塔医药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Reata制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧